Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/SFRP4_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SFRP4_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SFRP4_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SFRP4_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00301118 | Endometrium | AEH | regulation of Wnt signaling pathway | 71/2100 | 328/18723 | 3.31e-08 | 1.87e-06 | 71 |
GO:00160558 | Endometrium | AEH | Wnt signaling pathway | 85/2100 | 444/18723 | 4.99e-07 | 1.97e-05 | 85 |
GO:01987388 | Endometrium | AEH | cell-cell signaling by wnt | 85/2100 | 446/18723 | 6.07e-07 | 2.29e-05 | 85 |
GO:00608288 | Endometrium | AEH | regulation of canonical Wnt signaling pathway | 54/2100 | 253/18723 | 2.22e-06 | 6.56e-05 | 54 |
GO:00301777 | Endometrium | AEH | positive regulation of Wnt signaling pathway | 34/2100 | 140/18723 | 9.62e-06 | 2.23e-04 | 34 |
GO:00071787 | Endometrium | AEH | transmembrane receptor protein serine/threonine kinase signaling pathway | 67/2100 | 355/18723 | 1.28e-05 | 2.80e-04 | 67 |
GO:00482598 | Endometrium | AEH | regulation of receptor-mediated endocytosis | 28/2100 | 110/18723 | 2.28e-05 | 4.35e-04 | 28 |
GO:00600708 | Endometrium | AEH | canonical Wnt signaling pathway | 58/2100 | 303/18723 | 3.12e-05 | 5.66e-04 | 58 |
GO:00301009 | Endometrium | AEH | regulation of endocytosis | 44/2100 | 211/18723 | 3.39e-05 | 6.05e-04 | 44 |
GO:00068988 | Endometrium | AEH | receptor-mediated endocytosis | 49/2100 | 244/18723 | 3.54e-05 | 6.24e-04 | 49 |
GO:00902637 | Endometrium | AEH | positive regulation of canonical Wnt signaling pathway | 26/2100 | 106/18723 | 8.63e-05 | 1.27e-03 | 26 |
GO:00482608 | Endometrium | AEH | positive regulation of receptor-mediated endocytosis | 16/2100 | 52/18723 | 1.18e-04 | 1.66e-03 | 16 |
GO:00510515 | Endometrium | AEH | negative regulation of transport | 79/2100 | 470/18723 | 1.51e-04 | 1.99e-03 | 79 |
GO:00431128 | Endometrium | AEH | receptor metabolic process | 35/2100 | 166/18723 | 1.64e-04 | 2.15e-03 | 35 |
GO:00308564 | Endometrium | AEH | regulation of epithelial cell differentiation | 33/2100 | 154/18723 | 1.81e-04 | 2.32e-03 | 33 |
GO:00458078 | Endometrium | AEH | positive regulation of endocytosis | 24/2100 | 100/18723 | 2.27e-04 | 2.75e-03 | 24 |
GO:00316237 | Endometrium | AEH | receptor internalization | 26/2100 | 113/18723 | 2.62e-04 | 3.08e-03 | 26 |
GO:00305092 | Endometrium | AEH | BMP signaling pathway | 32/2100 | 152/18723 | 3.15e-04 | 3.54e-03 | 32 |
GO:00301785 | Endometrium | AEH | negative regulation of Wnt signaling pathway | 34/2100 | 170/18723 | 5.63e-04 | 5.62e-03 | 34 |
GO:00020902 | Endometrium | AEH | regulation of receptor internalization | 15/2100 | 56/18723 | 9.88e-04 | 8.90e-03 | 15 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SFRP4 | SNV | Missense_Mutation | rs140561432 | c.514C>T | p.Arg172Cys | p.R172C | Q6FHJ7 | protein_coding | tolerated(0.11) | benign(0.28) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
SFRP4 | SNV | Missense_Mutation | novel | c.486N>T | p.Gln162His | p.Q162H | Q6FHJ7 | protein_coding | tolerated(0.2) | benign(0) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
SFRP4 | SNV | Missense_Mutation | rs771031038 | c.929G>A | p.Arg310His | p.R310H | Q6FHJ7 | protein_coding | tolerated_low_confidence(0.11) | benign(0.001) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
SFRP4 | SNV | Missense_Mutation | rs748182253 | c.785G>A | p.Arg262His | p.R262H | Q6FHJ7 | protein_coding | tolerated(0.16) | possibly_damaging(0.616) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SFRP4 | SNV | Missense_Mutation | rs140561432 | c.514N>T | p.Arg172Cys | p.R172C | Q6FHJ7 | protein_coding | tolerated(0.11) | benign(0.28) | TCGA-BG-A0VZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
SFRP4 | SNV | Missense_Mutation | | c.722N>A | p.Ser241Tyr | p.S241Y | Q6FHJ7 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SFRP4 | SNV | Missense_Mutation | novel | c.541N>G | p.Lys181Glu | p.K181E | Q6FHJ7 | protein_coding | deleterious(0.04) | benign(0.345) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
SFRP4 | SNV | Missense_Mutation | rs771031038 | c.929N>A | p.Arg310His | p.R310H | Q6FHJ7 | protein_coding | tolerated_low_confidence(0.11) | benign(0.001) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
SFRP4 | SNV | Missense_Mutation | novel | c.613G>A | p.Ala205Thr | p.A205T | Q6FHJ7 | protein_coding | tolerated(0.1) | possibly_damaging(0.472) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SFRP4 | SNV | Missense_Mutation | novel | c.1024A>C | p.Asn342His | p.N342H | Q6FHJ7 | protein_coding | deleterious_low_confidence(0.01) | benign(0.125) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |